339 related articles for article (PubMed ID: 15564720)
21. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
[TBL] [Abstract][Full Text] [Related]
22. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
23. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
25. CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.
Shanehbandi D; Majidi J; Kazemi T; Baradaran B; Aghebati-Maleki L
Curr Cancer Drug Targets; 2017; 17(5):423-444. PubMed ID: 28067179
[TBL] [Abstract][Full Text] [Related]
26. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
27. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.
Sonoki T; Li Y; Miyanishi S; Nakamine H; Hanaoka N; Matsuoka H; Mori I; Nakakuma H
Int J Hematol; 2009 Apr; 89(3):400-402. PubMed ID: 19330555
[No Abstract] [Full Text] [Related]
28. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
29. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
30. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
Taylor RP; Lindorfer MA
Curr Opin Immunol; 2008 Aug; 20(4):444-9. PubMed ID: 18585457
[TBL] [Abstract][Full Text] [Related]
32. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.
Tobin E; Denardo G; Zhang N; Epstein AL; Liu C; Denardo S
Leuk Lymphoma; 2007 May; 48(5):944-56. PubMed ID: 17487739
[TBL] [Abstract][Full Text] [Related]
33. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.
Walshe CA; Beers SA; French RR; Chan CH; Johnson PW; Packham GK; Glennie MJ; Cragg MS
J Biol Chem; 2008 Jun; 283(25):16971-84. PubMed ID: 18426802
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects.
Renaudineau Y; Devauchelle-Pensec V; Hanrotel C; Pers JO; Saraux A; Youinou P
Joint Bone Spine; 2009 Oct; 76(5):458-63. PubMed ID: 19640767
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
36. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Tipton TR; Roghanian A; Oldham RJ; Carter MJ; Cox KL; Mockridge CI; French RR; Dahal LN; Duriez PJ; Hargreaves PG; Cragg MS; Beers SA
Blood; 2015 Mar; 125(12):1901-9. PubMed ID: 25631769
[TBL] [Abstract][Full Text] [Related]
37. [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
Hamaguchi Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):29-34. PubMed ID: 19252375
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
Bil J; Winiarska M; Nowis D; Bojarczuk K; Dabrowska-Iwanicka A; Basak GW; Sułek K; Jakobisiak M; Golab J
Blood; 2010 May; 115(18):3745-55. PubMed ID: 20200358
[TBL] [Abstract][Full Text] [Related]
39. The applications of anti-CD20 antibodies to treat various B cells disorders.
Payandeh Z; Bahrami AA; Hoseinpoor R; Mortazavi Y; Rajabibazl M; Rahimpour A; Taromchi AH; Khalil S
Biomed Pharmacother; 2019 Jan; 109():2415-2426. PubMed ID: 30551501
[TBL] [Abstract][Full Text] [Related]
40. Rituximab: mechanism of action.
Weiner GJ
Semin Hematol; 2010 Apr; 47(2):115-23. PubMed ID: 20350658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
